<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336728">
  <stage>Registered</stage>
  <submitdate>29/03/2011</submitdate>
  <approvaldate>10/05/2011</approvaldate>
  <actrnumber>ACTRN12611000484943</actrnumber>
  <trial_identification>
    <studytitle>A randomised, placebo-controlled trial of glycopyrrolate for the treatment of noisy respiratory secretions at the end of life-A pilot study</studytitle>
    <scientifictitle>A randomised, placebo-controlled trial of glycopyrrolate for the treatment of noisy respiratory secretions at the end of life-A pilot study</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Nosiy respiratory secretions at the end of life</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Any cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Glycopyrrolate 0.4mg initial subcutaneous dose immediately followed by continuous subcutaneous infusion of 1.2mg/24hours ( 0.05mg/hr) for a total of 24 hours.</interventions>
    <comparator>Normal saline delivered via the same method.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Feasibilty measure by acrrual of 24 patients in 12 months</outcome>
      <timepoint>3 months 
6 months
12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Interrater reliability of a Noisy respiratory secretions score (by two observers) and a noise meter.</outcome>
      <timepoint>Time points baseline, 30 minutes, 1 hour, 2 hours, 4 hours , 12 hours and 24 hours.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Age &gt; 18 years 
Life-limiting illness (malignant or non-malignant) 
Inpatient in a Palliative Care unit
Able to provide informed consent prior to entering the terminal phase
Willing to discuss end of life care.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Documented hypersensitivity to glycopyrrolate.
Glaucoma
Pregnant or Breastfeeding 
Estimated glomerular filtration rate (eGFR) &lt; 25 ml/min</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation by phone /fax /computer</concealment>
    <sequence>Simple randomisation by using a randomization table created by a computer software (i.e. computerised sequence generation)</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/06/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Caitlin Sheehan</primarysponsorname>
    <primarysponsoraddress>170 Darlinghurst Road
Darlinghurst NSW 2010</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Sacred Heart Reseach Fund</fundingname>
      <fundingaddress>170 Darlinghurst Road
Darlinghurst NSW 2010</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Professor David Currow</sponsorname>
      <sponsoraddress>Flinders University
700 Goodwood Road
Daw Park SA 5041</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study looks at the effect of a drug, called Glycopyrrolate, on noisy rattling breathing in palliative care patients at the end of life. Who is it for? You can join this study if you are an inpatient in a Palliative Care unit and are willing to discuss end of life care. Trial details Participants will be randomly divided into one of two groups. One group will receive a drug called Glycopyrrolate. This is administered via an injection followed by a continuous infusion (into the vein) for a duration of 24 hours . The other group will receive a placebo (sham) treatment also delivered in the same manner. The placebo has no expected treatment effect. Participants will not know which group they have been allocated to. This study aims to determine whether a larger scale trial of the drug, Glycopyrrolate, is feasible for the treatment of noisy rattling breathing at the end of life.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Not yet submitted</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincents Hospital HREC</ethicname>
      <ethicaddress>Victoria Street 
Darlinghurst 
NSW 2010</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>30/03/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Caitlin Sheehan</name>
      <address>Sacred Heart Hospice
170 Darlinghurst Road
Darlinhghurst 2010
New South Wales</address>
      <phone>+61 2 83829444</phone>
      <fax />
      <email>csheehan@stvincents.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Caitlin Sheehan</name>
      <address>Sacred Heart Centre
St Vincents Hospital
170 Darlinghurst Road
Darlinghurst 2010
New South Wales</address>
      <phone>+61 2 83829444</phone>
      <fax />
      <email>csheehan@stvincents.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Caitlin Sheehan</name>
      <address>170 Darlinghurst Road
Darlinghurst 2010
NSW</address>
      <phone>+61 2 83829444</phone>
      <fax />
      <email>csheehan@stvincents.com.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>